Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial

Author(s):
Fellstrom, B.C.; Barratt, J.; Cook, H.; Coppo, R.; Feehally, J.; Fijter, J.W. de; Floege, J.; Hetzel, G.; Jardine, A.G.; Locatelli, F.; Maes, B.D.; Mercer, A.; Ortiz, F.; Praga, M.; Sorensen, S.S.; Tesar, V.; Vecchio, L. del; NEFIGAN Trial Invest
Published
2017
Publication type
Article / Letter to editor
Date issued
2017-05-27
Language
English
Is part of
Lancet (2017), Vol. 389, no. 10084, p. 2117-2127
hdl
1887/94768
doi
10.1016/S0140-6736(17)30550-0